We report a novel approach in the treatment of spinal metastases with epidural disease and mechanical instability using a combined minimal access spine surgery (MASS) technique followed by spine stereotactic body radiotherapy (SBRT). This study was performed as a retrospective review of the first ten consecutive patients treated with this combined approach.
Introduction
As patients with metastatic cancer survive longer due to better systemic therapies, the optimal management of spinal metastases beyond traditional low dose conventional radiotherapy, or a simple posterior laminectomy, has been questioned. For example, more invasive direct circumferential decompression has recently been shown to be critical in the neurologic preservation of patients with symptomatic single level malignant epidural spinal cord compression (MESCC), (1) and reversed the dogma that radiation alone was the primary treatment for MESCC *Corresponding author: Dr. Eric Massicotte, M.D., F.R.C.S.C Phone: 416-603-5800 x5675 Fax: 416-603-5298 E-mail: eric.massicotte@uhn.on.ca Technology in Cancer Research & Treatment, Volume 11, Number 1, February 2012 with surgery reserved for salvage (2). However, direct decompressive surgery is indicated for only selected patients and criteria include those who are medically fit, a single level of MESCC, and a life expectancy of at least 3 months (1, 3) . This invasive surgery is not to be taken lightly as there are significant costs in terms of surgical morbidity (4), delays in receiving post-operative radiotherapy/chemotherapy, quality of life, and burden on the health care system. New less-invasive surgical approaches are being developed with the aim to reduce the morbidity of invasive open surgical procedures (4, 5), as the frequency of patients with MESCC requiring an operation is increasing. Minimal access spine surgery (MASS) technology is one such surgical technique. MASS allows for a less-invasive approach to reduce the morbidity of major open spine surgery while achieving the surgical goals of critical neural structure decompression (spinal cord and cauda equina) and maintenance of spine stability. MASS is established in the treatment of patients with degenerative spinal disease with benefits of less tissue trauma and less de-vascularized muscle, hence, lowering the rate of post-operative infection and the post-operative stay in hospital (6) (7) (8) (9) (10) (11) .
There are limited published experiences with minimally invasive techniques in the treatment of spine metastases (5, 12) . However, we are observing the emergence of several less invasive spine surgeries and in parallel with the advent of high dose spine stereotactic body radiotherapy (SBRT) (5, (13) (14) (15) . Spine SBRT is defined as the delivery of a high biologically effective dose (BED) to a spinal metastases (2-6 times those doses previously delivered) using conformal image-guided radiation technology (15) . The aim is to deliver a dose that is considered effective to not only palliate pain, but achieve durable long-term control (16) . One limitation to spine SBRT is the treatment of disease abutting the spinal cord/thecal sac, as this area is relatively under-dosed in order to maintain a safe dose limit to the critical neural structures (15, 17, 18) . Failure within the epidural space is a known pattern of failure primarily for this reason (15, (17) (18) (19) . Furthermore, it has been reported that those patients with disease compressing the thecal sac are at the highest risk of failure (18) . Our aim at the University of Toronto was to develop a minimally invasive surgical approach, performed as an out-patient day surgery procedure, where epidural disease is resected in patients who do not meet criteria for invasive direct decompressive surgery. The intent was to use this surgery as an adjunct to spine SBRT to improve upon the efficacy of SBRT, and to surgically palliate mechanical pain by stabilizing the affected vertebrae using methyl-methacrylate (MMA).
This report describes the use of MASS as a neo-adjuvant out-patient day surgery treatment in ten patients with spine metastases, epidural disease, and mechanical pain, followed by spine SBRT as practiced at the University of Toronto.
Methods
This study is a retrospective review of the first ten cases of spinal metastases treated with MASS followed by SBRT, and approved by the local Institutional Research and Ethics Board (IRB). Clinical information for all patients between January 2009 and July 2010 were collected prospectively, with IRB approval, including standardized questionnaires consisting of the oswestry disability index (ODI), visual analogue score (VAS) for pain, and the short-form 36 version 2 (SF-36 v2) to measure quality of life (QOL). All ten patients had pre-and post-operative imaging in the form of a CT scan and MRI spine. All but one patient was treated as an out-patient in our day surgery unit (DSU). This means that patients presented on the morning of their surgery to the DSU and were discharged on the same calendar day.
In each case, the grade of epidural disease was recorded according to Bilsky's criteria, (13) where zero is no epidural disease, 1a is epidural disease abutting the thecal sac with no thecal sac compression, 1b is epidural disease compressing the thecal sac without abutment of the spinal cord, 1c is epidural disease compressing the dura and abutting the spinal cord without compression, 2 is epidural disease compressing the spinal cord but cerebrospinal fluid is visible, and 3 is epidural disease compressing the spinal cord and cerebrospinal fluid not visible. All patients were diligently followed with physician visits and a complete MRI spine every 2 months.
Surgical Technique
Under general anesthesia, patients were placed in the prone position ensuring minimal abdominal pressure and maintenance of normal spinal alignment. Both of these factors help reduce venous congestion and potential for intra-operative blood loss. Prior to skin incision, each patient received a prophylactic dose of antibiotics, steroids and generous use of local anesthetic. The most direct route from the posterior approach was chosen through the paraspinal muscles. Direct visualization is essential for successful decompression and reconstruction of the affected level. Preoperative imaging (MRI, CT) was utilized, with intra-operative fluoroscopic imaging, to guide resection and reconstruction. The tubular retraction system used was developed by Medtronic (METRx, Memphis, TN, USA). The final tube measures 1.8 cm of internal diameter, and the length of the tube required was based on the thickness of the paraspinal muscles. Using the operating microscope, the bony surface of the posterior elements was visualized ( Figure 1 ). Once the tubular retractor was deployed, then a small amount of muscle overlying the bone was often removed to optimize visibility. The choice of microscope over endoscope is operator dependent. The microscope offers better depth perception while the endoscope permits different angles to be viewed by the surgeon. In this series, the operating microscope was used for all cases.
The need for drilling the posterior bony element was based on the amount of tumor-induced destruction. All our cases required varying degrees of drilling. The final channel needed to provide adequate visibility of the dura over both the spinal cord and the nerve root. Orientation was based on the dura and not the bony elements since the latter has either been removed or previously destroyed by the tumor. Tumor resection was then undertaken. If bleeding impeded resection, then bipolar cautery, packing with surgical foam, and use of various pro-thrombotic agents were applied. Decompression was confirmed using direct visualization, palpation, and intra-operative fluoroscopic images (Figure 1 ). Reconstruction of the vertebral body was indicated if there was a history of mechanical back pain (described as pain worse with motion and improved with recumbency), tenderness on palpation of the corresponding spinous process as opposed to the paraspinal musculature, and greater than 40% vertebral body bone destruction as per CT and MRI imaging. Reconstruction of the vertebral body with MMA involved cement placed directly into the cavity created within the vertebral body following tumor resection. Continually visualizing the cement, using intermittent fluoroscopic x-ray imaging, provided guidance as to how much cement to apply. The objective was to maximize the amount of cement required for the reconstruction, pushing the cement into all the crevasses, and leaving a safe margin with the dura. The range of MMA used for our cases was between 1 and 4 cc. Unlike the treatment of benign vertebral body compression fractures, where the aim is to increase the structural integrity of the entire vertebral body, our application focused on augmenting the integrity of the localized area of resection and, therefore, permitted a smaller volume of MMA to be applied. Once the cement was completely hard, closure was then performed. Attention was focused on having a block of MMA which would not dislodge and result in compression of the spinal cord. The upper thoracic level with its inherent kyphosis will increase this risk.
Post-operatively, patients were monitored in the post-anesthetic care unit for a minimum of one hour. Patients were then transferred to the DSU, where close monitoring was performed, and ambulation encouraged. Typically, six to eight hours after the operation patients were released home. Figures 1 and 2 illustrate the operative procedure.
SBRT Technique
Our technique has been published (20), but in brief we performed CT simulation with patients immobilized in the near-rigid BodyFIX immobilization system (Medical Intelligence, Schwabmuenchen, Germany). On the same day as CT simulation, the patient had a non-contrast enhanced MRI for purposes of image fusion in a Signa Infinity 1.5T TwinSpeed dedicated MRI simulator (General Electric Medical Systems, Milwaukee, WI). Treatment planning was performed using Pinnacle version 8.0 (Philips Medical Systems, Madison, WI). The gross tumor volume (GTV) was contoured and defined as radiographically visible tumor based on the fused CT/MRI images. The clinical target volume (CTV) was contoured, and defined as the margin applied to the GTV in order to encompass potential areas at risk of microscopic disease. The CTV also includes the ipsilateral trajectory of the tube. A planning target volume (PTV) was then applied as a 2 mm geometric expansion beyond the CTV limited at the spinal cord and/or thecal sac interface (if below the level of the spinal cord). The critical neural structures included the true spinal cord and/or the cauda equina, and the thecal sac itself. The critical neural structures were contoured well above and below the targeted vertebral segment. Typically, a 1.5 mm expansion was applied to the spinal cord as a planning organ at risk volume (PRV), and for the cauda equina the thecal sac had no applied PRV margin. Dose limits were set to either the thecal sac and/or cord PRV depending on whichever contour provides the safest practice. Treatment delivery consisted of step-and-shoot intensity modulated radiotherapy (IMRT) using 9-11 co-planar beams. All treatment were delivered using the Elekta ® Synergy S linear accelerator (Elekta, Crawley, UK) equipped with a 4 mm multi-leaf collimator, cone-beam CT (CBCT) image-guidance system, and HexaPOD robotic couch (Medical Intelligence, Schwabmuenchen, Germany). A CBCT was first taken to confirm set-up and correct any set-up positional errors in all six-degrees of freedom via the HexaPOD robotic couch. A mid-treatment CBCT was performed to determine if corrections were required to account for intra-fraction displacements. Typically, patient motion is maintained within 1.2 mm and 1 degree with 95% confidence in our experience (21).
At the University of Toronto, our choice of tumor dose and number of fractions is dependent on if prior radiation has been delivered, the volume of the target, number of vertebrae involved, and if epidural disease present. Single fraction is favored for small volumes, single vertebral level involvement, no prior radiation and when limited epidural disease is present. We typically aim for 80-90% coverage of the clinical target volume by the prescription dose, however, coverage is dictated by the limitation put on the surrounding organs at risk.
Results

Patient Characteristics
We summarize our inclusion and exclusion criteria in Table I and patient/treatment characteristics in Tables II and III . Key inclusion criteria for all patients included those with a single level of metastatic spine disease to be treated, presence of epidural tumour, and for whom radiation was considered the primary treatment modality. In no patient was there overt instability requiring instrumentation, nor acute symptomatic cord compression requiring urgent circumferential decompressive surgery.
All patients had thoracic or lumbar sites of disease and epidural disease compressing the thecal sac (Table III) . Only two patients had motor deficits secondary to epidural disease. Four patients had baseline vertebral compression fracture (VCF). Only one patient (#5) had been previously radiated to the spine (20 Gy in 5 fractions to the affected L3 area and a prior course of 46 Gy in 23 fractions to the pelvis with the superior border at the top of L4) and treated for progression. Eight of the ten patients had mechanical back pain at baseline, and two patients were asymptomatic with respect to pain. The indication for MASS in these two patients (Patients 9 and 10) primarily consisted of thecal sac decompression to maximize SBRT efficacy.
Post-MASS and SBRT Outcomes
In eight of the ten cases, based on the post-MASS MRI taken at the time of SBRT planning, decompression was achieved with no residual thecal sac compression. In two cases, residual thecal sac compression was observed, however, downgraded (Table II) . Intra-operative blood loss was minimal (Table II) , and the mean intra-operative blood loss was 335 ml. In one patient blood loss reached 1000 ml, while seemingly a large volume for MASS it is not unusual for spine surgery.
Other than one patient who was an admitted patient from an outside institution and transferred to the Toronto Western Hospital for MASS, all patients were treated as outpatients in the DSU and discharged home the same day. The number of days to SBRT planning ranged from 1 to 18. The SBRT treatment plan details for each patient are provided in Table IV . The median total dose was 24 Gy (range, 18-35 Gy), number of fractions 3 (range, 1-5), and the dose to 90% of the clinical target volume (CTVD90) was 22.6 Gy (17.5-30.9 Gy). The median follow-up for the cohort was 13 months (range, 3-18). Local control based on imaging was achieved in 7 of the 10 patients treated.
Local Failures
Patient 1 presented initially with oligometastatic non-small cell lung cancer (NSCLC) having with less than five sites of metastases and isolated to the bone [within the rib, femur, and spine (T9)]. The T9 metastases was treated with MASS followed by SBRT, and three months later he developed recurrent back pain and found to have a local in-field failure. However, he also developed widespread metastases throughout the bone, liver, and adrenal glands despite post-SBRT chemotherapy. He was treated for the painful local spinal recurrence with a course of conventional re-irradiation. In terms of the pattern of local failure, the disease progressed diffusely within the vertebral body and not within the epidural space. He died a few weeks later from systemic disease.
Patient 5 also suffered from a local recurrence post-SBRT to a L3 breast cancer metastases. This patient had sub-optimal disease characteristics at the start of treatment, where the patient initially had been treated with pelvic radiation where the superior border was at the top of L4 and then radiated with 20 Gy in 5 fractions for a L3 metastases that subsequently developed. She did not respond to the initial course of radiation and the L3 metastases progressed despite several lines of chemotherapy. She eventually was referred for SBRT due to a bulky (183 cc) and painful tumor. Six months post-SBRT, she presented with increased back pain and was found to have slight progression within the epidural space. Imaging at fourteen months post-SBRT has showed stable epidural disease with paraspinal disease progression.
Patient 7, with a T12 non-seminomatous germ cell metastasis, developed recurrent local epidural disease ten months post-SBRT, presenting with pain and MRI evidence of cord compression. He underwent a further MASS decompression and resection of the epidural tumor followed by a second course of SBRT. The patient remains controlled 2 months post-salvage MASS-SBRT.
Pain Control, QOL, and ODI
For the eight symptomatic patients at baseline, at 1 month post-MASS a median improvement of 1 point (range, 0-9) was observed (based on the VAS assessment for pain). At 5 months, the median improvement was 6 points (range, 3-7), and the improvement observed was preserved at the last follow-up for each patient. There were improvements in patient reported disability using the ODI with a 30% (range, 0-44) improvement at 1 month and a 50% improvement at 5 months, which was also maintained at the last follow-up for all patients. Global QOL was assessed using the SF-36v2 physical and mental domains. Maintenance of the physical domain of quality of life at 1 month and at 5 months was observed (median improvement of 0.6 points and 0.8 points respectively). Maintenance of the mental domain of quality of life at 1 month (median 0.5 point improvement), and significant improvements by 5 months (median 9.4 point improvement), were also observed. Maintenance of those improvements were also observed at the most recent patient assessment.
Acute Complications (Within 1 Month of MASS and SBRT)
One patient who was not included in this series deserves mention as his reconstruction failed shortly after MASS. In this patient with multiple medical co-morbidities, a T7 NSCLC metastases and grade 3 epidural disease, MASS was performed successfully with the patient discharged home from the DSU. He was not medically fit for open decompressive surgery. Two days following surgery, his back pain worsened and he acutely became myelopathic. The patient's MRI and CT indicated that the MMA had retropulsed into the epidural space and compressed the spinal cord. This 77 year-old patient refused salvage surgery and died shortly thereafter. He never presented for consideration of radiation and, therefore, not included in this series. Otherwise, only one patient had a small dural tear during the operation which was repaired during MASS.
Following SBRT, two patients had the acute complication of pain flare. This situation is described as pain transiently worsening within a week of treatment completion. Both patients required an increase in their pain medications and a short course of dexamethasone. No patient in this series was pre-medicated with dexamethasone prior to SBRT and no wound complications were observed.
Long-Term Complications (>1 Month Post-SBRT)
Three patients (patients 3, 4, and 6) had progressive VCF at last follow-up. Each of these patients had a baseline VCF and lytic metastatic disease within the vertebral body (VB). For patient 3, 4 and 6, the degree of baseline VB destruction was 90%, 90%, and 80%, and the relative progression in the degree of VCF was 80%, 50%, and 20% for each patient, respectively. The time to further collapse was 3, 6, and 2 months post-SBRT, respectively. In all cases, progression of the VCF was asymptomatic with no exacerbation in pain and no neurological deficits observed. No patient has yet to develop radiation myelopathy or any other significant radiation related late side effects.
Discussion
We describe in our first 10 patients treated with MASS and SBRT, preliminary efficacy with seven of the ten cases having tumor control at their last follow-up based on imaging. The MASS procedure is depicted in Figure 1 and Figure 2 , and a typical SBRT distribution and post-MASS MRI demonstrated in Figure 3 . Beyond crude local control, we report improvement in pain using the VAS, disability based on the ODI, and improvement in QOL according to the SF36v2 assessment tool.
MASS was selected as our surgical technique to decompress the critical neural structures and provide stability with the application of MMA, as these patients did not have indications for an invasive open circumferential decompression and instrumentation but had epidural disease and mechanical pain. Epidural disease is a limiting factor in local control rates with SBRT, (15) and mechanical pain is not palliated with radiation alone. Therefore, our goal was to offer these patients, that otherwise would not be operated upon, the potential benefits of decompression to maximize SBRT efficacy and treatment of the mechanical pain by stabilization with MMA. MASS has the additional benefits of minimizing surgical morbidity otherwise associated with invasive open procedures, and the limited incision minimizes delays to radiotherapy associated with traditional surgery. Although MASS has been used for patients with degenerative spinal conditions, (6-10) applying this technique to patients with neoplastic disease represents an area of expansion. This is a first report of MASS in conjunction with SBRT for spinal metastases.
Use of less invasive, or percutaneous, surgical approaches combined with SBRT is an active area of recent investigation for the spine (5, 13). Research in this area stems from the philosophy of SBRT (14, 25), where we are delivering ablative doses otherwise used in the curative setting to maximize tumor control to sites of metastatic disease (15). Therefore, our aim is to minimize the morbidity of traditional spine surgery, associated with maximally resecting the tumor bulk, by allowing SBRT to treat the residual disease. The surgery is, therefore, aimed primarily at decompression and stabilization.
Recently Moulding et al. reported on a series of 21 patients treated with a less invasive surgical approach followed by SBRT (13). All patients had at least epidural disease abutting the spinal cord (Grade 1C), and surgery consisted of a postero-lateral decompression with instrumentation to achieve the goal of epidural tumor decompression and stabilization. They report local failure in 4 patients (median follow-up 10.3 months). It is important to note that the operation is still invasive with instrumentation performed, and the time to subsequent SBRT was ~6 weeks post-op. Gerszten et al. reported on a percutaneous approach using a transpedicular coblation corpectomy, combined with closed fracture reduction and fixation, followed by SBRT (5). In his series of 12 patients, all had moderate spinal canal compromise (20-50% spinal canal compromise) and the mean time to SBRT post-surgery was 14 days (range, 2-20 days). No local failures were reported given a follow-up ranging from 7 to 44 months (median, 11 months). Our series with MASS compares favorably to the reported literature in terms of local control (Table V) , and is intermediate in the degree of invasiveness (Table VI) . In our series, the median time to SBRT planning was short at 6.5 days (range, 1-18) and treatment ensued on average 7 days following planning. The important observation is that patients were fit enough to tolerate BodyFIX immobilization, CT simulation and MRI simulation ~1 week after surgery.
For the eight symptomatic patients at baseline, we report at 5 months a median improvement in the VAS of 6 points (range, 3-7), 50% improvement in the reported disability using the ODI, maintenance of the SF-36v2 QOL physical domain, Figure 3 : This sequence illustrates the treatment for Patient 2. On the left is the pre-MASS axial T1 MRI and proceeding to the right is the post-MASS axial T1 MRI, a representative axial image of the spine SBRT treatment plan with selected isodose lines (patient treated with 24 Gy in 3 fraction), and the right most image is an axial T1 image at the last follow-up 10 months post-SBRT. and improvement in the SF-36v2 QOL mental domain. In the transpedicular coblation corpectomy combined with closed fracture reduction series by Gerszten et al., he also reports improvement in pain using the VAS that is not immediate but improves with time (similar to our observation). However, QOL was not reported in that series (5). The maintenance of QOL post-SBRT observed in this report is in accordance with the series reported by Degen et al. (22) for spine metastases treated with SBRT, however, their cohort did not comprise exclusively post-operative patients. Therefore, our data is consistent with the published literature.
The three local failures in this series deserve mention. Patient 5 had significant epidural disease (Grade 3) and was treated with MASS and SBRT for progressive symptomatic disease (pain and weakness in bilateral legs). This patient had been treated with prior radiation to the affected spine without response, and several lines of salvage chemotherapy following initial radiation. This patient likely had treatment resistant disease, and eventual progression with the patient presenting with a bulky mass (183 cc) prompted the referral for MASS-SBRT. Failure occurred 6 months post-SBRT which is within the expected time to progression post-SBRT in those who progress (18). Therefore, treatment likely delayed inevitable disease progression but the delay of 6 months allowed the patient to have time with less pain and improved mobility until symptoms recurred. The second patient (Patient 1) was found to have limited metastatic disease upon diagnosis of his lung cancer, and the T9 metastases with epidural disease treated with MASS and SBRT with the aim to be aggressive as he was young and fit. He was an ideal candidate with no history of prior radiation, T9 being the only site of metastatic disease within the spine, and treatment naïve with multiple lines of chemotherapy available to prolong survival. This patient failed 3 months post-SBRT while on chemotherapy, and when this patient failed he developed widespread metastatic disease throughout the spine, other bones, and liver. The rapid nature of his disease progression despite chemotherapy could indicate treatment resistant aggressive disease. The third patient (Patient 7) had the unusual tumor of a non-seminomatous germ cell tumor with spinal metastases. The patient's tumor was bulky at 202 cc, and had an extensive paraspinal component. He had failed several lines of chemotherapy and was progressing systemically with treatment resistant disease when he presented for MASS-SBRT. The pattern of failure was predominantly within the epidural space, and he presented with neurologic deficits of motor weakness and pain. He has been successfully salvaged with a second course of MASS-SBRT and is well with two months of follow-up.
In terms or complications, one fatal event occurred due to cement extravasation rendering the patient myelopathic. Although he had initial MESCC and was not a candidate for an open surgery due to significant medical co-morbidities, this case demonstrates the potential for this technique to cause complications. This patient refused any further intervention to correct the cement extravasation and he died shortly thereafter. Cement extravasation is a known complication with kyphoplasty or vertebroplasty procedures, however, it is a rare occurrence (23). This event highlights that significant complications can occur with MASS, and careful consideration is required during MMA application and in choosing the location within the spine that is appropriate. Otherwise the procedure was well tolerated with one patient having a dural tear that was repaired at the time of MASS. No significant wound complications are reported despite the short time interval to SBRT.
In three patients VCF progressed, and each had pre-existing VCF at baseline and lytic metastatic disease. Fracture progression was an asymptomatic event in each patient. New or progressive VCF is a known complication post-SBRT occurring in 39% of treated patients in one SBRT series (13). Further follow-up and larger patient numbers are required before we can conclude that MMA and our MASS technique is sufficient to prevent progression of VCF; however, none of the six patients without VCF have yet to develop this complication. Intraoperative blood loss was minimal in our series, and the mean intra-operative blood loss was 335 ml. We do caution that the MASS technique requires significant consideration to tumor type and the expected blood loss. The restricted view when working through the tubular retraction presents a challenge for the surgeon. Even a small volume of blood can obstruct the view by filling the tube with an internal diameter of 1.8 cm leaving the neural structure of interest at risk. Therefore, tumor types like renal cell have not been treated using this technique to date, and we are now cautious in considering thyroid metastases.
The options for managing metastatic spine tumors continue to evolve. Even within the mainstays of treatment, surgery and radiotherapy, there is a spectrum of approaches that ranges from the least invasive to maximally invasive (or aggressive) (Table VI) . The options are more apparent for surgery, as radiation typically has been limited to conventional low dose radiotherapy. Surgical intervention can range from intra-lesional resections, using either open or MASS techniques, to en-bloc maximally invasive resections (24). The drawbacks to invasive surgery lies in the risks of surgical morbidity and the potential delays in receiving post-operative radiotherapy/chemotherapy which can directly impact outcomes of survival. The aim of MASS is to offer the potential benefits of resecting epidural disease to decompressing the spinal cord prior to overt symptomatic MESCC, and offer stabilization to palliate mechanical pain, as an adjunct to the definitive therapy of SBRT.
Conclusion
We report on the unique application of MASS using a tubular retraction system to achieve the surgical goals of critical neural structure decompression and mechanical stabilization followed by spine SBRT. Patients were treated in an out-patient DSU, minimal intra-operative blood losses were observed, and the median time to SBRT treatment planning was only 6.5 days. Outcomes of local control, pain control and QOL were favorable and consistent with the published literature. We conclude preliminary efficacy and safety for this novel therapeutic approach with the caveat that mature follow-up is required and a larger experience before this therapy is widely adopted.
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